The global peptide therapeutics market was valued at USD 101.20 billion in 2025. It is estimated at USD 112.20 billion in 2026 and is forecast to reach USD 229.32 billion by 2036, rising at a CAGR of 7.4% over 2026-2036. The report assesses approved products and their sales, patent expiry and generic entry, the pipeline, delivery technologies, manufacturing and CDMO capacity, regulation and pricing, and competition.
The study covers approved medicines whose active ingredient is a peptide, usually a chain of roughly 2 to 50 amino acids, whether linear, cyclic, lipidated, or conjugated, and whether made by chemical synthesis or recombinant methods. It spans incretins, hormone analogs such as leuprolide, octreotide, teriparatide, and vosoritide, oncology agents such as carfilzomib and radionuclide therapies, complement and immune-modulating drugs such as pegcetacoplan and glatiramer acetate, gut-acting drugs such as linaclotide and teduglutide, and anti-infectives. Insulins and larger proteins, peptide vaccines, and small molecules that act on peptide receptors, such as non-peptide oral GLP-1 drugs, fall outside the scope.
Incretin peptides have reshaped the field, with Eli Lilly reporting 2025 revenue of USD 22.97 billion for Mounjaro, up 99%, and USD 13.54 billion for Zepbound, up 175%, both based on tirzepatide, while Novo Nordisk's Ozempic, Wegovy, and Rybelsus remain among the best-selling medicines in the world. The patient pool is very large: the International Diabetes Federation estimates that about 589 million adults aged 20 to 79 had diabetes in 2024, and the World Health Organization estimates that more than 1 billion people were living with obesity in 2022.
Value growth is held back because most peptides are broken down in the gut and must be injected, and even oral semaglutide needs high doses and strict fasting conditions. Synthesis is complex and capital-intensive; the U.S. FDA listed semaglutide and tirzepatide as in shortage from 2022 until late 2024 and early 2025. Prices are under pressure: according to Lilly, weaker realized pricing reduced revenue in its U.S. diabetes and obesity business by roughly 5% in the final quarter of 2025, Medicare negotiated prices for semaglutide begin in 2027, and older molecules from liraglutide to leuprolide face generic copies. Compounded and unapproved online peptides also divert patients. Other challenges include solvent waste from solid-phase synthesis, which the EU's December 2023 REACH limit on dimethylformamide addresses, impurity and immunogenicity rules for complex generics, short half-lives, and rival oral small molecules, antibodies, and siRNA drugs.
The largest opportunities lie in oral and macrocyclic peptides, peptide radioligands and conjugates, and generics and outsourced manufacturing. The FDA cleared the Wegovy tablet in December 2025, and two macrocyclic pills, Merck & Co.'s enlicitide for LDL cholesterol and icotrokinra from Johnson & Johnson and Protagonist Therapeutics for psoriasis, have succeeded in Phase 3. Peptides can carry isotopes or drugs to tumor cells, as Novartis' Lutathera does with lutetium-177, and the International Agency for Research on Cancer counted about 20 million new cancer cases worldwide in 2022. Semaglutide patent expiry in 2026 in China, India, Canada, and Brazil opens a large generic opportunity for experienced API makers and CDMOs. Key trends include multi-agonist incretins, pill-based peptides, a race for capacity, and greener hybrid, flow, and enzymatic synthesis. According to Novo Holdings, it paid USD 16.5 billion for Catalent in 2024, adding fill-finish sites for Novo Nordisk.
By peptide class, the report covers GLP-1 & incretin peptides (semaglutide, tirzepatide, and liraglutide, dulaglutide & others), hormone analogs (GnRH, somatostatin, PTH & PTHrP, calcitonin, vasopressin & oxytocin, and CNP analogs), oncology peptides & radioligands (proteasome inhibitors, peptide receptor radionuclide therapy, and peptide-drug conjugates), plus immunomodulatory & complement, gastrointestinal, and anti-infective & other peptides. GLP-1 & incretin peptides are expected to hold the largest share in 2026, given the scale of semaglutide and tirzepatide sales, a widening list of approved indications, and once-weekly dosing that supports long-term use. Oncology peptides & radioligands are expected to grow at the highest CAGR, as new radioligands target additional cancer receptors, peptide-drug conjugates offer better tumor penetration than antibody conjugates, and large drug makers invest in radiopharmaceutical capabilities. Hormone analogs remain a sizable class, although many face generic competition.
By type, the market is split into innovative and generic peptides. Innovative peptides are expected to account for the larger share in 2026, as patent-protected incretins such as tirzepatide, whose Mounjaro and Zepbound franchises reached USD 36.5 billion in 2025 according to Lilly, generate most of the value, and branded rare disease peptides carry high prices per patient. Generic peptides are expected to register the higher CAGR, supported by semaglutide patent expiry in 2026 in China, India, Canada, and Brazil, continued generic entry for liraglutide and older hormone analogs, and the readiness of many Chinese and Indian manufacturers.
By route of administration, the study covers parenteral (subcutaneous, intravenous, and intramuscular & depot), oral, and other routes (nasal, inhaled, and transdermal). Parenteral delivery is expected to hold the largest share in 2026, because once-weekly incretin injections and depot formulations of hormone analogs dominate treated volume and most peptides cannot survive the digestive tract. Oral delivery is expected to grow at the highest CAGR, as the Wegovy pill reaches patients and macrocyclic candidates such as enlicitide and icotrokinra could challenge injectable antibodies in heart and immune disease.
By structure, the report covers linear peptides, cyclic & macrocyclic peptides, and lipidated & conjugated peptides. The lipidated and conjugated group includes the weekly incretins and carrier-linked long-acting products. Cyclic and macrocyclic designs are gaining attention because cyclization improves stability and can enable oral absorption, as seen in the late-stage PCSK9 and IL-23 receptor programs, while linear peptides include many established hormone analogs.
By manufacturing technology, the report covers solid-phase peptide synthesis, liquid-phase & hybrid synthesis, and recombinant production. Solid-phase synthesis is the standard route for most peptide APIs, but its heavy solvent use and waste are pushing manufacturers toward hybrid approaches that combine solid- and liquid-phase steps, fragment condensation, continuous-flow processing, and enzymatic ligation. Recombinant expression suits longer sequences, and Bachem, PolyPeptide, CordenPharma, and WuXi TIDES are adding capacity.
By application, the report covers metabolic disorders (type 2 diabetes and obesity), oncology, rare & endocrine disorders, gastrointestinal disorders, immunology & neurology, cardiovascular disorders, infectious diseases, and others. Metabolic disorders are expected to hold the largest share in 2026, reflecting the use of incretin peptides across very large diabetes and obesity populations and new label expansions. Rare & endocrine disorders are expected to grow at the highest CAGR, as specialty peptides such as Voxzogo, Yorvipath for hypoparathyroidism, and Rhythm Pharmaceuticals' setmelanotide for rare genetic obesity gain uptake across more countries.
By distribution channel, the market is divided into retail pharmacies, hospital pharmacies, and specialty & online pharmacies. Retail pharmacies are expected to hold the largest share in 2026, since most incretin prescriptions are filled through community pharmacies. Specialty & online pharmacies are expected to grow at the highest CAGR, as drug makers sell incretins directly to patients and rare disease peptides move through specialty networks.
North America is expected to hold the largest share of the market in 2026, backed by wide incretin use, premium pricing, and a deep base of peptide innovators. Lilly's domestic diabetes and obesity revenue grew 54% to roughly USD 10 billion in the last quarter of 2025, according to the company, and a Medicare Part D pilot began covering obesity drugs in April 2026. Canada is among the first markets where semaglutide generics can enter in 2026. Europe holds a significant share as home to Novo Nordisk and to Ipsen, Zealand Pharma, Ascendis Pharma, Bachem, PolyPeptide, and CordenPharma, although stricter pricing and reimbursement controls limit obesity drug uptake.
Asia-Pacific is expected to grow at the highest CAGR during the forecast period, driven by large and rising diabetes and obesity populations, expanding access to incretins, and generic entry after semaglutide patents expire in China and India in 2026. Chinese and Indian manufacturers, including API producers such as WuXi TIDES, are building capacity for domestic and export supply, and Japan, South Korea, and Australia remain key buyers of branded peptides. In Latin America, semaglutide expiry in Brazil and high diabetes and obesity rates in Brazil, Mexico, and Argentina favor lower-priced generics. In the Middle East & Africa, well-funded Gulf health systems with high diabetes rates support incretin access.
The market is led by two incretin companies, Novo Nordisk and Eli Lilly, alongside older hormone and cancer drug franchises, specialty developers, generic makers, and API and contract manufacturers. Rivalry turns on efficacy, dosing convenience, manufacturing scale, patents, pricing, and pipeline depth. Main strategies include multi-agonist and oral peptide development, new indications, capacity expansion, preparation for generic competition, and licensing, as shown by Zealand Pharma's March 2025 partnership with Roche on the amylin analog petrelintide, which brought USD 1.65 billion in upfront payments according to the companies.
Key companies profiled in the report include Novo Nordisk A/S (Denmark), Eli Lilly and Company (U.S.), Amgen Inc. (U.S.), AbbVie Inc. (U.S.), Novartis AG (Switzerland), Ipsen S.A. (France), Teva Pharmaceutical Industries Ltd. (Israel), Ironwood Pharmaceuticals, Inc. (U.S.), BioMarin Pharmaceutical Inc. (U.S.), Ascendis Pharma A/S (Denmark), Apellis Pharmaceuticals, Inc. (U.S.), UCB S.A. (Belgium), Rhythm Pharmaceuticals, Inc. (U.S.), Zealand Pharma A/S (Denmark), Protagonist Therapeutics, Inc. (U.S.), Johnson & Johnson (U.S.), Merck & Co., Inc. (U.S.), Bachem Holding AG (Switzerland), PolyPeptide Group AG (Switzerland), CordenPharma (Germany), and WuXi TIDES (WuXi AppTec) (China).
The study covers approved medicines whose active ingredient is a peptide, usually a chain of roughly 2 to 50 amino acids, whether linear, cyclic, lipidated, or conjugated, and whether made by chemical synthesis or recombinant methods. It spans incretins, hormone analogs such as leuprolide, octreotide, teriparatide, and vosoritide, oncology agents such as carfilzomib and radionuclide therapies, complement and immune-modulating drugs such as pegcetacoplan and glatiramer acetate, gut-acting drugs such as linaclotide and teduglutide, and anti-infectives. Insulins and larger proteins, peptide vaccines, and small molecules that act on peptide receptors, such as non-peptide oral GLP-1 drugs, fall outside the scope.
Incretin peptides have reshaped the field, with Eli Lilly reporting 2025 revenue of USD 22.97 billion for Mounjaro, up 99%, and USD 13.54 billion for Zepbound, up 175%, both based on tirzepatide, while Novo Nordisk's Ozempic, Wegovy, and Rybelsus remain among the best-selling medicines in the world. The patient pool is very large: the International Diabetes Federation estimates that about 589 million adults aged 20 to 79 had diabetes in 2024, and the World Health Organization estimates that more than 1 billion people were living with obesity in 2022.
Market Dynamics
Growth is led by incretin peptides, which mimic gut hormones that control blood glucose and appetite and have won added labels in heart, kidney, sleep apnea, and liver disease. Next-generation multi-agonists such as retatrutide and CagriSema are in late development. Aging populations lift demand for hormone analogs in cancer and osteoporosis, and few eligible patients outside the U.S. and Europe receive incretins today. Rare and endocrine diseases are a second growth engine: according to BioMarin, sales of Voxzogo, its peptide for achondroplasia, rose 26% in 2025 across 55 commercial markets. Lipidation, cyclization, PEGylation, and carrier platforms such as Ascendis' TransCon have turned short-lived native peptides into weekly or longer-acting drugs.Value growth is held back because most peptides are broken down in the gut and must be injected, and even oral semaglutide needs high doses and strict fasting conditions. Synthesis is complex and capital-intensive; the U.S. FDA listed semaglutide and tirzepatide as in shortage from 2022 until late 2024 and early 2025. Prices are under pressure: according to Lilly, weaker realized pricing reduced revenue in its U.S. diabetes and obesity business by roughly 5% in the final quarter of 2025, Medicare negotiated prices for semaglutide begin in 2027, and older molecules from liraglutide to leuprolide face generic copies. Compounded and unapproved online peptides also divert patients. Other challenges include solvent waste from solid-phase synthesis, which the EU's December 2023 REACH limit on dimethylformamide addresses, impurity and immunogenicity rules for complex generics, short half-lives, and rival oral small molecules, antibodies, and siRNA drugs.
The largest opportunities lie in oral and macrocyclic peptides, peptide radioligands and conjugates, and generics and outsourced manufacturing. The FDA cleared the Wegovy tablet in December 2025, and two macrocyclic pills, Merck & Co.'s enlicitide for LDL cholesterol and icotrokinra from Johnson & Johnson and Protagonist Therapeutics for psoriasis, have succeeded in Phase 3. Peptides can carry isotopes or drugs to tumor cells, as Novartis' Lutathera does with lutetium-177, and the International Agency for Research on Cancer counted about 20 million new cancer cases worldwide in 2022. Semaglutide patent expiry in 2026 in China, India, Canada, and Brazil opens a large generic opportunity for experienced API makers and CDMOs. Key trends include multi-agonist incretins, pill-based peptides, a race for capacity, and greener hybrid, flow, and enzymatic synthesis. According to Novo Holdings, it paid USD 16.5 billion for Catalent in 2024, adding fill-finish sites for Novo Nordisk.
Segment Analysis
The report analyzes the market by peptide class, type, route of administration, structure, manufacturing technology, application, distribution channel, and geography, showing where value sits today and where new growth is forming.By peptide class, the report covers GLP-1 & incretin peptides (semaglutide, tirzepatide, and liraglutide, dulaglutide & others), hormone analogs (GnRH, somatostatin, PTH & PTHrP, calcitonin, vasopressin & oxytocin, and CNP analogs), oncology peptides & radioligands (proteasome inhibitors, peptide receptor radionuclide therapy, and peptide-drug conjugates), plus immunomodulatory & complement, gastrointestinal, and anti-infective & other peptides. GLP-1 & incretin peptides are expected to hold the largest share in 2026, given the scale of semaglutide and tirzepatide sales, a widening list of approved indications, and once-weekly dosing that supports long-term use. Oncology peptides & radioligands are expected to grow at the highest CAGR, as new radioligands target additional cancer receptors, peptide-drug conjugates offer better tumor penetration than antibody conjugates, and large drug makers invest in radiopharmaceutical capabilities. Hormone analogs remain a sizable class, although many face generic competition.
By type, the market is split into innovative and generic peptides. Innovative peptides are expected to account for the larger share in 2026, as patent-protected incretins such as tirzepatide, whose Mounjaro and Zepbound franchises reached USD 36.5 billion in 2025 according to Lilly, generate most of the value, and branded rare disease peptides carry high prices per patient. Generic peptides are expected to register the higher CAGR, supported by semaglutide patent expiry in 2026 in China, India, Canada, and Brazil, continued generic entry for liraglutide and older hormone analogs, and the readiness of many Chinese and Indian manufacturers.
By route of administration, the study covers parenteral (subcutaneous, intravenous, and intramuscular & depot), oral, and other routes (nasal, inhaled, and transdermal). Parenteral delivery is expected to hold the largest share in 2026, because once-weekly incretin injections and depot formulations of hormone analogs dominate treated volume and most peptides cannot survive the digestive tract. Oral delivery is expected to grow at the highest CAGR, as the Wegovy pill reaches patients and macrocyclic candidates such as enlicitide and icotrokinra could challenge injectable antibodies in heart and immune disease.
By structure, the report covers linear peptides, cyclic & macrocyclic peptides, and lipidated & conjugated peptides. The lipidated and conjugated group includes the weekly incretins and carrier-linked long-acting products. Cyclic and macrocyclic designs are gaining attention because cyclization improves stability and can enable oral absorption, as seen in the late-stage PCSK9 and IL-23 receptor programs, while linear peptides include many established hormone analogs.
By manufacturing technology, the report covers solid-phase peptide synthesis, liquid-phase & hybrid synthesis, and recombinant production. Solid-phase synthesis is the standard route for most peptide APIs, but its heavy solvent use and waste are pushing manufacturers toward hybrid approaches that combine solid- and liquid-phase steps, fragment condensation, continuous-flow processing, and enzymatic ligation. Recombinant expression suits longer sequences, and Bachem, PolyPeptide, CordenPharma, and WuXi TIDES are adding capacity.
By application, the report covers metabolic disorders (type 2 diabetes and obesity), oncology, rare & endocrine disorders, gastrointestinal disorders, immunology & neurology, cardiovascular disorders, infectious diseases, and others. Metabolic disorders are expected to hold the largest share in 2026, reflecting the use of incretin peptides across very large diabetes and obesity populations and new label expansions. Rare & endocrine disorders are expected to grow at the highest CAGR, as specialty peptides such as Voxzogo, Yorvipath for hypoparathyroidism, and Rhythm Pharmaceuticals' setmelanotide for rare genetic obesity gain uptake across more countries.
By distribution channel, the market is divided into retail pharmacies, hospital pharmacies, and specialty & online pharmacies. Retail pharmacies are expected to hold the largest share in 2026, since most incretin prescriptions are filled through community pharmacies. Specialty & online pharmacies are expected to grow at the highest CAGR, as drug makers sell incretins directly to patients and rare disease peptides move through specialty networks.
Regional Analysis
The report covers North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa, with analysis of 21 countries and five rest-of-region groups.North America is expected to hold the largest share of the market in 2026, backed by wide incretin use, premium pricing, and a deep base of peptide innovators. Lilly's domestic diabetes and obesity revenue grew 54% to roughly USD 10 billion in the last quarter of 2025, according to the company, and a Medicare Part D pilot began covering obesity drugs in April 2026. Canada is among the first markets where semaglutide generics can enter in 2026. Europe holds a significant share as home to Novo Nordisk and to Ipsen, Zealand Pharma, Ascendis Pharma, Bachem, PolyPeptide, and CordenPharma, although stricter pricing and reimbursement controls limit obesity drug uptake.
Asia-Pacific is expected to grow at the highest CAGR during the forecast period, driven by large and rising diabetes and obesity populations, expanding access to incretins, and generic entry after semaglutide patents expire in China and India in 2026. Chinese and Indian manufacturers, including API producers such as WuXi TIDES, are building capacity for domestic and export supply, and Japan, South Korea, and Australia remain key buyers of branded peptides. In Latin America, semaglutide expiry in Brazil and high diabetes and obesity rates in Brazil, Mexico, and Argentina favor lower-priced generics. In the Middle East & Africa, well-funded Gulf health systems with high diabetes rates support incretin access.
Competitive Landscape
The report reviews key growth strategies, competitive benchmarking, and the competitive dashboard, which places companies among industry leaders, market differentiators, vanguards, and emerging companies, along with a market share/rank analysis by key player for 2025. Profiles, with financials, portfolios, developments, and SWOT analyses, are grouped into incretin leaders, established franchises, specialty and rare disease developers, oral peptide innovators, and API and CDMO specialists.The market is led by two incretin companies, Novo Nordisk and Eli Lilly, alongside older hormone and cancer drug franchises, specialty developers, generic makers, and API and contract manufacturers. Rivalry turns on efficacy, dosing convenience, manufacturing scale, patents, pricing, and pipeline depth. Main strategies include multi-agonist and oral peptide development, new indications, capacity expansion, preparation for generic competition, and licensing, as shown by Zealand Pharma's March 2025 partnership with Roche on the amylin analog petrelintide, which brought USD 1.65 billion in upfront payments according to the companies.
Key companies profiled in the report include Novo Nordisk A/S (Denmark), Eli Lilly and Company (U.S.), Amgen Inc. (U.S.), AbbVie Inc. (U.S.), Novartis AG (Switzerland), Ipsen S.A. (France), Teva Pharmaceutical Industries Ltd. (Israel), Ironwood Pharmaceuticals, Inc. (U.S.), BioMarin Pharmaceutical Inc. (U.S.), Ascendis Pharma A/S (Denmark), Apellis Pharmaceuticals, Inc. (U.S.), UCB S.A. (Belgium), Rhythm Pharmaceuticals, Inc. (U.S.), Zealand Pharma A/S (Denmark), Protagonist Therapeutics, Inc. (U.S.), Johnson & Johnson (U.S.), Merck & Co., Inc. (U.S.), Bachem Holding AG (Switzerland), PolyPeptide Group AG (Switzerland), CordenPharma (Germany), and WuXi TIDES (WuXi AppTec) (China).
How This Report Helps
- Provides reliable market size estimates and long-term forecasts for the global peptide therapeutics market through 2036.
- Explains how incretin peptides, rare disease peptides, and engineering advances are shaping demand and value.
- Assesses the effect of pricing pressure, semaglutide patent expiry, generic entry, and compounded products on market value.
- Identifies high-growth opportunities across peptide class, type, route, structure, manufacturing technology, application, channel, and region.
- Tracks the pipeline of multi-agonist incretins, oral macrocyclic peptides, radioligands, and peptide-drug conjugates.
- Reviews peptide manufacturing technologies, CDMO capacity, and green chemistry rules.
- Supports portfolio strategy, licensing, manufacturing investment, and market entry decisions for drug developers, generic makers, CDMOs, and investors.
Key Questions Answered
- How large is the global peptide therapeutics market today, and how will it grow through 2036?
- How will multi-agonist incretins and oral peptides change the incretin market, and how will prices evolve?
- What are the main drivers, restraints, opportunities, challenges, and trends shaping the market?
- How will semaglutide patent expiry in 2026 affect generic entry, pricing, and access by country?
- Which peptide class, type, route, structure, manufacturing technology, application, and channel segments will grow the fastest?
- Which late-stage oral, radioligand, and rare disease peptides could reach the market during the forecast period?
- Which regions and countries offer the most attractive opportunities?
- Who are the leading peptide developers and manufacturers, and how do they compare?
- What acquisitions, partnerships, approvals, and capacity investments are shaping competition?
Table of Contents
1. Introduction
2. Research Methodology
4. Market Overview
5. Peptide Therapeutics Market, by Peptide Class
6. Peptide Therapeutics Market, by Type
7. Peptide Therapeutics Market, by Route of Administration
8. Peptide Therapeutics Market, by Structure
9. Peptide Therapeutics Market, by Manufacturing Technology
10. Peptide Therapeutics Market, by Application
11. Peptide Therapeutics Market, by Distribution Channel
12. Peptide Therapeutics Market, by Geography
13. Competitive Landscape
14. Company Profiles
15. Appendix
LIST OF TABLES
LIST OF FIGURES
Companies Mentioned
- Novo Nordisk A/S
- Eli Lilly and Company
- Amgen Inc.
- AbbVie Inc.
- Novartis AG
- Ipsen S.A.
- Teva Pharmaceutical Industries Ltd.
- Ironwood Pharmaceuticals, Inc.
- BioMarin Pharmaceutical Inc.
- Ascendis Pharma A/S
- Apellis Pharmaceuticals, Inc.
- UCB S.A.
- Rhythm Pharmaceuticals, Inc.
- Zealand Pharma A/S
- Protagonist Therapeutics, Inc.
- Johnson & Johnson
- Merck & Co., Inc.
- Bachem Holding AG
- PolyPeptide Group AG
- CordenPharma
- WuXi TIDES
